Christopher Latour, MD
Cardiovascular Disease · Jackson, MSNPI 1508247560
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $23,610 of the $33,329 with a category attached, or 70.8%. Lexicon Pharmaceuticals, Inc. accounts for 77.4% of it on its own, with 35 other manufacturers making up the rest. Reporting peaked in 2024 at $28,849 and has fallen 96.0% since, to $1,166 in 2025. Among cardiovascular disease clinicians in MS with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 285 payments — averaging $116.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lexicon Pharmaceuticals, Inc.$26K
- Edwards Lifesciences$2K
- Abbott$762
- Novartis$706
- Boston Scientific$599
- Pfizer$564
- plus $3K from 30 others
What the payments were for
- Speaking & faculty fees$23,61071%
- Travel & lodging$3,0589%
- Food & beverage$6,62920%
- Education$320%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lexicon Pharmaceuticals, Inc. | 29 | $25,793 |
| Edwards Lifesciences | 13 | $1,733 |
| Abbott | 12 | $762 |
| Novartis | 47 | $706 |
| Boston Scientific | 16 | $599 |
| Pfizer | 37 | $564 |
| E.r. Squibb & Sons, L.L.C. | 32 | $437 |
| Amgen | 14 | $367 |
| AstraZeneca | 6 | $278 |
| Abiomed | 3 | $238 |
| Alnylam Pharmaceuticals Inc. | 9 | $234 |
| Novo Nordisk | 11 | $227 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $200 |
| Johnson & Johnson | 11 | $151 |
| Boehringer Ingelheim | 4 | $112 |
| Astellas Pharma US Inc | 5 | $105 |
| Itamar Medical Inc | 1 | $104 |
| BTG International Inc. | 1 | $101 |
| Atricure, Inc. | 3 | $75 |
| Braemar Manufacturing, LLC | 1 | $73 |
| Merck | 4 | $68 |
| Canon Medical Systems USA, Inc. | 2 | $62 |
| Gilead | 3 | $47 |
| Baxter Healthcare | 1 | $35 |
| Irhythm Technologies, Inc. | 2 | $33 |
| Akcea Therapeutics, Inc. | 2 | $31 |
| Regeneron Healthcare Solutions, Inc. | 1 | $24 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $23 |
| Lantheus Medical Imaging, Inc. | 2 | $23 |
| Medtronic | 1 | $22 |
| Actelion Pharmaceuticals US, Inc. | 1 | $21 |
| Bridgebio Pharma, Inc. | 1 | $18 |
| Recor Medical Inc | 1 | $17 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Cardiovascular Systems Inc. | 1 | $15 |
| Angiodynamics, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Inpefa$25,455
- PASCAL$1,257
- MitraClip$451
- FARXIGA$225
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$145
- EMBOLD Fibered$133
- Repatha$124
- Impella$105
- WatchPATONE$104
- EKOSONIC$101
How this compares
$33,329 in reported general payments places this provider in the 90th percentile of 144 cardiovascular disease providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 24 | $622,889 |
| CamzyosMavacamten | 28 | $226,975 |
| EliquisApixaban | 277 | $224,957 |
| JardianceEmpagliflozin | 121 | $91,924 |
| EntrestoSacubitril/Valsartan | 90 | $82,195 |
| Repatha SureclickEvolocumab | 82 | $52,913 |
| XareltoRivaroxaban | 29 | $33,172 |
| MounjaroTirzepatide | 16 | $21,036 |
| FarxigaDapagliflozin Propanediol | 31 | $18,700 |
| OzempicSemaglutide | 13 | $12,986 |
| Metoprolol Succinate | 381 | $3,327 |
| Bisoprolol Fumarate | 93 | $2,282 |
| Atorvastatin Calcium | 217 | $1,450 |
| Nifedipine ErNifedipine | 77 | $1,438 |
| Ranolazine ErRanolazine | 23 | $1,397 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $564 | $847,846301 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $437 | $226,97528 claims |
| Boehringer IngelheimJardiance | $112 | $91,924121 claims |
| NovartisEntresto | $706 | $82,19590 claims |
| Johnson & JohnsonXarelto | $151 | $33,17229 claims |
| AstraZenecaFarxiga | $278 | $18,70031 claims |
| Novo NordiskOzempic | $227 | $12,98613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 144 cardiovascular disease providers in Mississippi.
Other cardiovascular disease in Jackson
- Donny StokesJackson$207K
- James BenslerJackson$64K
- Michael HallJackson$54K
- Tahsin QarqishJackson$39K
- Varun SardarJackson$31K
- Olurotimi BaderoJackson$20K
- Michael PaymentJackson$16K
- James HaysJackson$16K
- Douglas HarkinsJackson$14K
- Aditya SabharwalJackson$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.